The ERRS MODEL incorporates various techniques recommended by the FDA to evaluate the safety of trademarks, including Failure Mode and Effects Analysis (FMEA)  which is used in conjunction with expert panel analysis. It also utilizes practitioner survey results as one source of hypothesis generation.

A pre-marketing approach, the ERRS MODEL allows us to proactively help prevent medication errors by testing for potential look-alike and sound-alike confusion with proposed trademarks. The ERRS MODEL also helps identify potential regulatory issues that may render a trademark “unapprovable.” Though used for single country or international reviews for proprietary trademarks, the ERRS MODEL can be used to test proposed nonproprietary names, as well.

We recognize that each client has specific requests, so the ERRS MODEL has been designed to adapt to these requests. This adaptability also allows us to meet emerging regulatory guidelines.